Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in treatments for therapeutic resistance, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Jacob M. Chacko, M.D., will deliver a company overview presentation on Tuesday, January 14, 2025, at 11:15 a.m. PT.
The presentation will be accessible via live webcast through the investor section of ORIC's website at www.oricpharma.com. Interested parties who cannot attend the live presentation will have access to a replay of the webcast, which will remain available for 90 days after the event.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced the granting of inducement awards to a new non-executive employee who joined in December 2024. The grants, approved on January 2, 2025, include 16,400 non-qualified stock options and 2,800 restricted stock units.
The stock options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years. The restricted stock units will vest in three equal installments on each anniversary of the grant date. The exercise price for the stock options is set at the closing price of ORIC's common stock on January 2, 2025.
These inducement grants were made under the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, announced its participation in two upcoming investor conferences in December 2024. The company will join a fireside chat at the 7th Annual Evercore HEALTHCONx Conference on December 4 at 2:35 p.m. ET, and participate in the 'Novel Mechanisms in Oncology II' panel at Citi's 2024 Global Healthcare Conference on December 5 at 11:00 a.m. ET. Live webcasts will be accessible through ORIC's website, with replays available for 90 days after the events.
ORIC Pharmaceuticals reported Q3 2024 financial results and operational updates. The company presented preclinical data for ORIC-114, demonstrating potential best-in-class properties for treating EGFR exon 20 insertions. They announced clinical collaborations with Bayer and Johnson & Johnson for ORIC-944 trials in prostate cancer. Financial highlights include cash and investments of $282.4 million, expected to fund operations into late 2026. R&D expenses increased to $31.2 million in Q3 2024 from $22.4 million in Q3 2023, while G&A expenses rose to $7.1 million from $6.3 million in the same period.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in two upcoming investor conferences in November 2024. The company will be featured in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference on November 11 at 10:30 a.m. ET and the Jefferies London Healthcare Conference on November 21 at 12:00 p.m. GMT. Live webcasts of both discussions will be accessible through ORIC's investor website section, with replays available for 90 days after the events.
ORIC Pharmaceuticals announced the granting of inducement equity awards to two new non-executive employees who joined in October 2024. The grants include 61,800 non-qualified stock options and 10,400 restricted stock units. The stock options will vest 25% after one year, with remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals presented data highlighting ORIC-114's potential as a best-in-class EGFR/HER2 inhibitor for treating EGFR exon 20 insertions and other atypical mutations. The brain-penetrant, orally bioavailable treatment demonstrated superior potency across EGFR mutational classes compared to other inhibitors. Key findings showed tumor regressions in all tested EGFR mutant models, with 100% tumor regressions in complex atypical mutant EGFR models. The drug displayed superior kinome selectivity and complete molecular responses in ctDNA from patients. Updated data from Phase 1b expansion cohorts is expected in H1 2025.
Candid Therapeutics, a clinical stage biotechnology company focused on T-cell engagers for autoimmune diseases, has appointed Angie You, Ph.D. and Dan Puckett to its board of directors. Dr. You, currently CEO of Architect Therapeutics, brings extensive experience in scaling organizations and advancing innovative products. She previously led Amunix Pharmaceuticals to a $1.2 billion acquisition by Sanofi. Mr. Puckett, former CFO of Shockwave Medical, played a key role in the company's growth leading to its $13.1 billion acquisition by Johnson & Johnson in 2024.
Ken Song, Chairman, President and CEO of Candid Therapeutics, expressed confidence that these proven leaders will be invaluable resources as the company aims to become a leader in treating autoimmune diseases. Both new board members have expressed enthusiasm for Candid's potential to transform autoimmune disease treatment through T-cell engagers.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced a poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, scheduled for October 23-25, 2024, in Barcelona, Spain. The poster, titled "ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against exon 20 insertions and other atypical EGFR mutations," will be presented on October 23, 2024.
ORIC-114 is described as a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor targeting EGFR and HER2 mutations. Preclinical analysis showed ORIC-114's superior properties compared to other inhibitors, including brain penetrance, kinome selectivity, and potent activity against various EGFR mutations. The drug has demonstrated clinical responses in patients with EGFR and HER2 exon 20 insertion mutations, including those with CNS metastases. ORIC-114 is currently being evaluated in a global clinical trial (NCT05315700).
ORIC Pharmaceuticals, a clinical stage oncology company, announced on October 4, 2024, that it granted 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who joined in September 2024. These inducement grants, approved on October 1, 2024, are part of ORIC's 2022 Inducement Equity Incentive Plan and are subject to continued employment.
The stock options have an exercise price equal to ORIC's closing stock price on the grant date. 25% of the stock options will vest after one year, with the remaining vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants, approved by ORIC's Compensation Committee, comply with Nasdaq Rule 5635(c)(4) as material inducements to employment.
